Details of the Drug

General Information of Drug (ID: DMK3U1X)

Drug Name
ALT-803
Synonyms IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [1]
Bladder cancer 2C94 Phase 2 [2]
Non-hodgkin lymphoma 2B33.5 Phase 1/2 [3]
Non-small-cell lung cancer 2C25.Y Phase 1/2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
Human immunodeficiency virus infection 1C62 Phase 1 [5]
Multiple myeloma 2A83 Phase 1 [2]
Pancreatic cancer 2C10 Phase 1 [3]
⏷ Show the Full List of Indication(s)
Cross-matching ID
TTD ID
D0FD7H
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 15 receptor alpha (IL15RA) TTGN89I I15RA_HUMAN Agonist [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03050216) QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02384954) ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15;73(10):3075-86.